COMMUNIQUÉS West-GlobeNewswire

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it [...]
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
02/10/2026
First patient expected to be dosed in the DUET study in the fourth quarter of 2026 Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds SOUTH SAN [...]
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
02/10/2026
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year [...]
Persephone Biosciences to Provide 50,000 Free Doses of Groundbreaking Infant and Toddler Synbiotics
02/10/2026
90% of U.S. infants lack key beneficial microbes necessary for optimal development Deficient microbiomes associated with non-vaginal births, formula feeding and chronic antibiotic use have been linked to asthma, eczema [...]
Celcuity Appoints David Gryska To Its Board Of Directors
02/10/2026
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s Board MINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing [...]
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/10/2026
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies [...]
Hyperion DeFi Commences Share Buybacks, Retires All Legacy Debt, and Commits to Further Capital Optimization
02/10/2026
DALLAS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced it has repurchased 240,124 HYPD common shares at a weighted average price of $3.21* per [...]
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
02/10/2026
Based on a post hoc analysis, a majority of participants (~70%) experienced clinically meaningful tic reduction within 8 weeks of starting ecopipam An interim 18-month analysis of an ongoing open-label extension study [...]
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
02/10/2026
The published review examines dopamine’s role in tic generation and how approved and investigational drugs may affect dopamine to reduce tics as well as synthesizes clinical trial evidence that ecopipam reduces tic [...]
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
02/10/2026
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter [...]
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
02/10/2026
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall Patent reinforces [...]
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
02/10/2026
Major Institutional Formulary Win Expands Arbli ™ ’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially Arbli ™ Addresses an Approximately $219 Million U.S. Losartan Market Representing [...]
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
02/10/2026
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes CNTY-813 IND [...]
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
02/10/2026
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early [...]
Guidepoint Qsight Reports Male Neurotoxin Spending Exceeds $500 Per Visit for the First Time
02/10/2026
New York, USA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Males Spend Also Outweighs Women’s Qsight patient transaction data shows male neurotoxin average spend per transaction in Q3-to-date at $529, the highest Qsight has ever [...]
Addex Therapeutics Announces Executive Management Changes
02/10/2026
Jean-Philippe Rocher Appointed Head of Pharmaceutical Development Mikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex [...]
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
02/10/2026
BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational [...]
Ending MS Is Within Reach: National MS Society Raises a Record-Breaking $12 Million to Launch the Campaign to End MS
02/10/2026
Nearly 500 guests gathered at Cipriani 42nd Street for the Campaign to End MS Gala, emceed by Ginger Zee and honoring David Osmond and his family, as the Society kicked off its five-year, $1 billion campaign NEW YORK, [...]
Wandercraft Acquires Ekso Bionics, Uniting Two Pioneers to Advance and Expand Robotic Mobility
02/10/2026
End-to-end continuum of care, powered by medical exoskeletons, an expanded global clinical network, and trailblazing R&D capabilities, expands options for upright mobility, from rehabilitation to everyday life NEW [...]

Pages